gamma-carboline has been researched along with phenothiazine in 2 studies
| Studies (gamma-carboline) | Trials (gamma-carboline) | Recent Studies (post-2010) (gamma-carboline) | Studies (phenothiazine) | Trials (phenothiazine) | Recent Studies (post-2010) (phenothiazine) |
|---|---|---|---|---|---|
| 44 | 0 | 26 | 2,553 | 7 | 191 |
| Protein | Taxonomy | gamma-carboline (IC50) | phenothiazine (IC50) |
|---|---|---|---|
| NADPH oxidase 1 | Homo sapiens (human) | 0.3589 | |
| rac GTPase-activating protein 1 isoform a | Homo sapiens (human) | 18.5 | |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 2.236 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.016 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.461 | |
| Polyunsaturated fatty acid 5-lipoxygenase | Rattus norvegicus (Norway rat) | 1.4 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 4.643 | |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | 0.592 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 0.196 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.461 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 2.236 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.532 | |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | 0.94 | |
| Prostaglandin G/H synthase 1 | Rattus norvegicus (Norway rat) | 0.94 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arndt, HD; Gaube, F; Raztsou, I; Robaa, D; Rohrbach, MM; Sager, H; Schätz, B; Schwarthoff, S; Tischer, N; Winckler, T | 1 |
| Aksinenko, AY; Aliev, G; Bachurin, SO; Barreto, GE; Boltneva, NP; Grigoriev, VV; Lushchekina, SV; Makhaeva, GF; Serebryakova, OG; Sokolov, VB; Vikhareva, EA | 1 |
2 other study(ies) available for gamma-carboline and phenothiazine
| Article | Year |
|---|---|
Evaluation of γ-carboline-phenothiazine conjugates as simultaneous NMDA receptor blockers and cholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Carbolines; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neuroprotective Agents; Phenothiazines; Receptors, N-Methyl-D-Aspartate; Structure-Activity Relationship | 2021 |
Conjugates of γ-Carbolines and Phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer Disease.
Topics: Alzheimer Disease; Animals; Binding Sites; Butyrylcholinesterase; Carbolines; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Drug Design; Enzyme Activation; Humans; Models, Chemical; Molecular Docking Simulation; Phenothiazines; Protein Binding; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 2015 |